Europe small molecule contract development and manufacturing organization (CDMO) market was valued at $ 17,340.6 million in 2021 and will grow by 6.2% annually over 2021-2031, driven by the increasing demand for small molecule medicines and therapies, a rising demand for cost control in drug development, the increasing incidence of disease, and rising healthcare expenditures.
Highlighted with 34 tables and 52 figures, this 111-page report “Europe Small Molecule Contract Development and Manufacturing Organization (CDMO) Market 2021-2031 by Product Type (API, FDF), Service Type (Preclinical, Clinical, Commercial), Customer Type (Pharmaceutical Firms, Biotechnology Firms), Therapeutic Area (Infectious Diseases, Oncology, Ophthalmology, Cardiovascular Disorders, Central Nervous System, Respiratory Disorders, Metabolic Diseases), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe small molecule contract development and manufacturing organization (CDMO) market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2019-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:

  • Market Structure
  • Growth Drivers
  • Restraints and Challenges
  • Emerging Product Trends & Market Opportunities
  • Porter’s Fiver Forces


The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify Europe small molecule contract development and manufacturing organization (CDMO) market in every aspect of the classification from perspectives of Product Type, Service Type, Customer Type, Therapeutic Area, and Country.

Based on Product Type, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.

  • Active Pharmaceutical Ingredients (API)


o Branded Drugs
o Generic Drugs

  • Finished Dosage Formulations (FDF)


o Oral Solid Drugs
o Injectable Drugs
o Semi-solid or Liquid Drugs
o Other FDFs

Based on Service Type, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.

  • Preclinical Use
  • Clinical Use


o Phase I
o Phase II
o Phase III
o Phase IV

  • Commercial Use



By Customer Type, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.

  • Pharmaceutical Firms
  • Biotechnology Firms



By Therapeutic Area, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.

  • Infectious Diseases
  • Oncology
  • Ophthalmology
  • Cardiovascular Disorders
  • Central Nervous System
  • Respiratory Disorders
  • Metabolic Diseases
  • Other Therapeutic Areas



Geographically, the following national/local markets are fully investigated:

  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe (further segmented into Russia, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)


For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of national markets by Product Type, Service Type and Therapeutic Area over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
Boehringer Ingelheim
Cambrex Corporation
Catalent
Cipla
Covance Inc.
Lonza Group Ltd.
Medley Pharmaceuticals
NatcoPharma
Patheon (Thermo Fisher Scientific, Inc.)
Piramal Pharma Solutions
RedHillBiopharma
Siegfried Holding AG
STA Pharmaceutical
Sun Pharmaceutical
Teva
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)